Directional Deep Brain Stimulation: First experiences in centers across the globe
Objective: To evaluate how clinicians are implementing directional DBS technology in their routine care. Background: Directional DBS is a new technology, which increases the clinician’s…Challenging mitochondria in idiopathic Parkinson‘s disease fibroblasts
Objective: Evaluate mitochondrial integrity in cultivated fibroblasts of patients with idiopathic Parkinson’s disease (IPD) and healthy controls (HC). Background: Mitochondrial dysfunction (MD) is considered an…The effectiveness of boxing exercise in elderly patients including Parkinson’s disease patients
Objective: To clarify the effect of boxing exercise on balance, muscle strength and mobility in elderly patients with chronic disease including Parkinson’s disease (PD). Background:…Weight variation in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion
Objective: To compare weight variations between three cohorts of patients with advanced Parkinson’s disease (PD): patients during their first year of treatment either with levodopa-carbidopa…A clinical tool to ensure delivery of modern personalised medicine for Parkinson’s disease: first description of a personalised medicine checklist
Objective: To field test a clinically relevant checklist to ensure that health care professionals (HCP) are prompted to consider the various enablers of personalised medicine…Association analysis of the nutritional status and serum nutritional index in patients with Parkinson’s disease
Objective: This study was conducted to determine the associations between the nutritional status and serum nutritional index and motor symptoms among patients with Parkinson’s disease(PD).…Ondansetron, a highly-selective 5-HT3 receptor antagonist, alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of selective serotonin 3 (5-HT3) receptor blockade at reducing the severity of established, and preventing the development of, dyskinesia. Background:…Effects of JN403, an α-7-nicotine-acetylcholine-receptor (α7-nAChR) agonist on human alpha-synuclein-mediated in vitro and in vivo models of Parkinson’s disease
Objective: To investigate whether JN403, a novel selective agonist of α-7-nicotine-acetylcholine-receptors (α7-nAChRs) can suppress inflammation and toxicity in human alpha-synuclein (αSyn) induced in vitro and…Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and subdivided by their baseline OFF-time. Background: OPC,…A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease
Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…
- « Previous Page
- 1
- …
- 133
- 134
- 135
- 136
- 137
- …
- 177
- Next Page »